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Abstract
Cancer can be viewed as a set of different diseases with distinctions based on tissue origin,
driver mutations, and genetic signatures. Accordingly, each of these distinctions have been
used to classify cancer subtypes and to reveal common features. Here, we present a differ-
ent analysis of cancer based on amino acid mutation signatures. Non-negative Matrix Fac-
torization and principal component analysis of 29 cancers revealed six amino acid mutation
signatures, including four signatures that were dominated by either arginine to histidine
(Arg>His) or glutamate to lysine (Glu>Lys) mutations. Sample-level analyses reveal that
while some cancers are heterogeneous, others are largely dominated by one type of muta-
tion. Using a non-overlapping set of samples from the COSMIC somatic mutation database,
we validate five of six mutation signatures, including signatures with prominent arginine
to histidine (Arg>His) or glutamate to lysine (Glu>Lys) mutations. This suggests that our
classification of cancers based on amino acid mutation patterns may provide avenues of
inquiry pertaining to specific protein mutations that may generate novel insights into cancer
biology.
Introduction
Cancers have been described as open, complex, and adaptive systems [1]. Reflecting this, can-
cer progression is determined in part by genetic diversification and clonal selection within
complex tissue landscapes and with changing tumor properties and microenvironment fea-
tures [2, 3]. Genetic sequencing of tumor samples has been critical in developing the evolu-
tionary theory of cancer. While cancers traditionally have been—and continue to be—
classified by tissue of origin, genetic sequencing has allowed for classification based on driver
mutations [4] or nucleotide mutation signatures [5]. However, cancer cell adaptation is medi-
ated by changes at the protein level that alter cell biology and enable cancer cell behaviors such
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as increased proliferation and cell survival. Existing cancer classifications by nucleotide muta-
tion signatures lack a link between the underlying genetic landscape and effects on cancer cell
phenotypes. Analysis of cancers by amino acid mutations could provide important connec-
tions between cancer evolution and adaptive biological phenotypes as well as provide insight
into how specific classes of amino acid mutations may generally alter the function of the pro-
teins in which they are found. There have been some studies to examine amino acid mutations
across cancers [6–8], but these have relied on simple mutation counting methods.
Here we take a machine-learning approach to analyze amino acid mutations across 29
cancers in order to identify characteristic amino acid mutation signatures. Our analyses re-
veal that some cancer types have mutation signatures dominated by arginine to histidine
(Arg>His) mutations, some have signatures dominated by glutamate to lysine (Glu>Lys), and
others have more complex signatures that lack a single dominant amino acid mutation. These
signatures were further validated in a non-overlapping set of samples from the COSMIC
somatic mutation database. Importantly, this approach identifies not only which amino acid
mutations are prevalent among cancers but also which amino acid mutations tend to occur
together. For example, cancers with strong Arg>His signatures will also frequently have many
Ala>Thr mutations but are unlikely to have many Glu>Lys mutations (despite all of these
amino acid transitions resulting from a G>A nucleotide mutation).
Results
Several cancers are enriched for R>H and E>K amino acid mutations
Multiple studies have interrogated nucleotide mutation biases by analyzing somatic variation
across a wide range of cancers [4, 5]. However, in protein coding regions of the genome (i.e.
the exome), it is essential to study patterns of amino acid variation to reveal information about
potential functional effects at the protein level. We characterized the global properties of
amino acid mutations encoded by somatic mutations across a range of cancers by analyzing a
tumor-normal paired mutation database [5] consisting of 6,931 samples across 29 cancer
types. We applied filtering to remove sequencing artifacts and restricted mutation data to non-
synonymous amino acid mutations (see Materials and Methods, S1 Table and S2 Table for
details).
Using this amino acid mutation database, we performed an unbiased characterization of
mutation signatures across cancer types using Non-negative Matrix Factorization (NMF),
which has proven to be a useful tool for pattern discovery in cancer tissue mutation datasets
[5] and other biological systems [9]. Applying NMF to the pooled mutation data reveals six
mutation signatures at the amino acid level (S1G Fig), including two with strong Arg>His
components and two with strong Glu>Lys components (Fig 1A, S1 Fig). Although the cancers
are comprised of a mixture of the signatures identified, ten cancers (AML, colorectal, esoph-
ageal, low grade glioma, kidney chromophobe, medulloblastoma, pancreatic, prostate, stom-
ach, and uterine) have majority contributions from Arg>His-prominent mutation signatures
(R>H and A>T/R>H). We also identify four cancers (bladder, cervix, head and neck, and
melanoma) that have majority contributions from Glu>Lys-prominent mutation signatures
(E>K and E>K/E>Q). Additionally, there are two complex signatures not dominated by any
particular amino acid mutation. Glioblastoma, kidney papillary, liver, and thyroid cancers
have majority contribution from the Complex 1 signature, and lung adenocarcinoma, small
cell lung, squamous cell lung, and neuroblastoma cancers all have majority contribution from
the Complex 2 signature. Finally, seven cancers from a variety of tissues (ALL, breast, CLL,
clear cell kidney, B-cell lymphoma, myeloma, and ovarian) have heterogeneous mutation sig-
nature contributions.
R>H and E>K mutations are prominent features in many cancers
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Visualizing amino acid mutation properties with principal component
analysis
To alternatively visualize the amino acid mutation spectrum, we use principal component
analysis to reveal cancers clustering by dominant mutation classes (Fig 1B). We find that PC1
separates Arg>His dominant cancers from Glu>Lys dominant cancers and that PC2 separates
cancers with more complex signatures (S2 Fig). This result reinforces our observation that
Arg>His and Glu>Lys mutations are characteristic signatures of several cancers.
Individual cancer samples recapitulate amino acid mutation patterns
We also analyze samples individually with NMF and find that Arg>His and Glu>Lys features
continue to dominate (Fig 2A and S3 Fig). For many cancer subtypes (melanoma, bladder,
uterine, colorectal, low-grade glioma, cervix, neuroblastoma, and the three different lung can-
cers), individual patients within each cancer exhibit consistent amino acid signatures (Fig 2B).
This is true even within clinically diverse cancers such as bladder, uterine, colorectal, and lung
cancer, which all have multiple identified driver mutations. This suggests that the amino acid
signatures we identified may be independent of underlying driver mutations and may instead
be a consequence of common features of the cancer, tumor microenvironment, or selective
pressures, all of which may be targeted therapeutically.
As NMF decomposes a sample into a mixture of characteristic signatures, we can further
visualize the normalized mixture coefficients from the individual-level NMF along the three
mutation signatures with dominant Arg>His or Glu>Lys components (R>H, E>K, and
E>K/E>Q signatures; Fig 3) to determine whether samples tend to be an equal mixture of
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Fig 1. Arg>His and Glu>Lys mutations define mutation signatures of a subset of cancers. (A) Heatmap representation of six-component NMF
clustering. Of the six amino acid mutation signatures identified, four have prominent charge-changing mutations: Arg>His (R>H), Glu>Lys (E>K), or
Glu>Gln (E>Q). Two complex signatures were also identified. Color scale represents scaled contribution of each signature for a given cancer type.
Signature and NMF fit details can be found in S1 Fig. (B) Principal component analysis of nonsynonymous amino acid mutations. PC1 separates
cancers with high R>H from cancers with high E>K; PC2 separates cancers with complex signatures. Colors represent the greatest mutation
signature contributing to a given cancer. Individual PC loadings can be found in S2 Fig.
https://doi.org/10.1371/journal.pone.0183273.g001
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several signatures or whether they tend to be exclusively composed of a single signature.
Indeed, Fig 3 shows a clear separation of samples with a high proportion of Glu>Lys from
other signatures.
Mutation signature validation
We validated the NMF signatures with an orthogonal data set (see Materials and Methods)
from the COSMIC database [10]. The six mutation signatures identified from COSMIC (S4
Fig) overlap substantially with previously identified signatures (S3 Fig). We calculated correla-
tion coefficients between all COSMIC Data signatures and each Alexandrov Data signature.
When the correlations are very high, this indicates that NMF has identified the same general
mutation signature in the two different data sets. Indeed, we found high correlation between
the COSMIC signatures and our initially identified signatures for five of the six (Fig 4): R>H,
E>K, E>K/E>Q, Complex 2, and Complex A are replicated. The Complex B signature does
not replicate as a separate signature, but appears to be largely incorporated into the other com-
plex signatures. Interestingly, a new R>Q/R>W signature is identified as a separate compo-
nent in the COSMIC data. On inspection of the Alexandrov R>H component we identified,
we see that R>Q and R>W are prominent components. Increased sample size in our replicate
data set likely enabled NMF to discriminate between these two signatures in COSMIC.
Discussion
Proteomic changes can allow cancer cells to adapt to dynamic pressures including changes in
matrix composition, oxygen and nutrient availability, intracellular metabolism, as well as
increased intracellular pH (pHi), the latter enabling tumorigenic cell behaviors [11–15]. Our
analyses reveal that a subset of all possible amino acid mutations dominate the mutation land-
scape of cancers, with Glu>Lys and Arg>His mutations being the most prominent features of
identified mutation signatures.
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Fig 2. Amino acid mutation signatures for individual samples. (A) A heatmap representation of the six-component NMF clustering
results for individual cancer samples (only those with >10 total nonsynonymous mutations). Samples with the same maximum signature
component were grouped and sorted. Four amino acid mutation signatures identified (R>H, E>K, E>K/E>Q, Complex 2) overlap with
signatures in Fig 1A. Color scale represents scaled contribution of each signature for a given sample. Signature and NMF fit details can be
found in S3 Fig. (B) Bars show the total fraction of individual samples with a majority of a particular signature within each cancer. Within
cancers, a large fraction of individual samples tend to have similar signature components.
https://doi.org/10.1371/journal.pone.0183273.g002
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Fig 3. Normalized NMF mixture coefficients for individual samples. Plot of the normalized mixture coefficients across the three mutation signatures
with high R>H or E>K components for every individual sample. Colors represent the greatest contributing mutation signature for each sample based on the
full individual-level NMF analysis. Here we see a dramatic separation of samples in the E>K component to the near exclusion of other signatures.
https://doi.org/10.1371/journal.pone.0183273.g003
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Charge-changing mutations, whether buried or surface-exposed, can alter protein charge,
electrostatics, and conformation [16]. Electrostatics of surface residues have been shown to
play a key role in protein-protein interactions [17], protein-membrane interactions [18, 19],
and kinase substrate recognition [20]. While it is important to note that our analyses are
agnostic to the location of the mutation within the proteome and within a protein, the strong
bias towards amino acid mutations that alter charge in our identified mutation signatures may
suggest an adaptive advantage conferred by these mutations.
Glu>Lys mutations swap a negatively charged amino acid for a positively charged amino
acid, which may in some cases affect protein function. Indeed, in some cases buried lysine
mutations can induce global protein unfolding upon charging that alters mutant protein stabil-
ity and function [21]. Furthermore, Glu>Lys mutations have been known to affect the func-
tion of PIK3CA [22–24].
Arg>His mutations swap a positively charged amino acid for a titratable amino acid.
Whereas arginine (pKa ~12) should always be protonated, histidine (pKa ~6.5) can titrate
within the narrow physiological pH range. Indeed, the pH-sensitive function of many wild-
type proteins has been shown to be mediated by titratable histidine residues [25–27]. More-
over, recent work has shown that some Arg>His mutations can confer pH sensitivity to the
mutant protein and alter function [28]. We predict that some Arg>His mutations may be
adaptive to increased pHi, conferring a gain in pH sensing to the mutant protein.
From our analyses, Arg>His mutations define the mutation landscape of a diverse set of
cancers across a range of tissues including brain (low-grade glioma), digestive (colorectal),
Fig 4. Correlations of COSMIC and Alexandrov mutation signatures. For each COSMIC mutation signature
we calculated the correlation with each Alexandrov mutation signature. Five of six Alexandrov mutation
signatures replicate in the COSMIC data for k = 6 mutation signatures. Alexandrov Signature R>H is replicated
by COSMIC Signature 1, although a subset of mutation types that clustered in the original R>H are identified in
the larger COSMIC data set as Signature 2. Alexandrov Signature E>K is replicated by COSMIC Signature 4.
Alexandrov Signature E>K, E>Q is replicated by COSMIC Signature 5, although it is also correlated with
COSMIC Signature 4 as each of these signatures share mutations. Alexandrov Signature Complex 2 is
replicated by COSMIC Signature 6. Alexandrov Signature Complex A is replicated by COSMIC Signature 3.
Alexandrov Signature Complex B is not faithfully replicated by any single COSMIC Signature, as the signal
appears to be spread amongst COSMIC Signatures 3, 5 and 6.
https://doi.org/10.1371/journal.pone.0183273.g004
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reproductive (uterine), and blood (AML) cancers. Importantly, these cancers do not have
overlapping nucleotide mutation signatures [5], which suggests that the amino acid mutation
signatures we identified may reflect other aspects of the cancers including distinct physiologi-
cal pressures, microenvironment features, or functional requirements. Indeed, these results
may help inform studies in the emerging field of Molecular Pathologic Epidemiology (MPE)
[29, 30], which seeks to integrate knowledge across disciplines to inform personalized ap-
proaches to cancer prevention and therapy. Linking amino acid signatures to physiological or
pathological features of the cancer could be important for identifying selective pressures that
may be driving or sustaining the cancer as well as for limiting disease progression, particularly
where targeted approaches fail [31–33].
Materials and methods
Mutation dataset filtering
We validated the dataset [5] by comparing known frequencies of well-studied cancer driver
genes with observed frequencies in the dataset. Specifically, BRAF is mutated in 40–50% of
melanoma samples, and IDH1 is mutated in 75–85%, low-grade glioma, AML, and glioblas-
toma samples are mutated 75–85%, 8–12%, and 1–5% of the time, respectively. We used the
p53 database (http://p53.fr/index.html) to find expected p53 mutation frequency for various
cancers: colorectal, head and neck, pancreatic, stomach, liver, and breast cancer have 43%,
42%, 34%, 32%, 31%, and 22% p53 mutation rates, respectively. The observed mutation fre-
quencies were consistently lower than expected for the genes/cancers we assessed, which sug-
gests that the dataset authors [5] were perhaps too stringent in quality control (QC) filtering.
Different levels of QC filtering were performed, and we systematically relaxed filters in order
to recapitulate the expected mutation frequencies of the selected canonical driver genes.
Applying only the ‘sequencing artifact’ QC filter (from [5]) most closely recapitulated expected
mutation frequencies for the canonical driver genes, and this filter alone was used for the
remainder of the bioinformatics analyses.
Mapping somatic SNPs
After filtering we used part of the PolyPhen2 [34] pipeline to map mutations to UCSC Canoni-
cal transcripts and restricted to nonsynonymous amino acid changes. The following cancers
had reduced sample sizes after filtering and nonsynonymous mutation restriction: AML: one
sample eliminated through QC filtering, two samples eliminated because all mutations were
synonymous; low grade glioma: one sample eliminated because after QC filtering all remaining
mutations were synonymous; glioblastoma: two samples eliminated because all mutations
were synonymous. All Pilocytic Astrocytoma samples were excluded from future analysis due
to low total nonsynonymous mutations per sample.
Mutation frequency data sets
For the individual sample data, we represent each sample as a row vector with elements giving
the mutation counts observed for each nonsynonymous mutation (e.g. Ala>Cys, Ala>Asp,
etc.) and removing all samples with<10 total observed mutations. For the aggregated data set,
we sum the mutation counts across all samples of the same cancer type (including samples
with<10 mutations), giving one row vector for each cancer type where each element repre-
sents the total number of observed nonsynonymous mutations across all samples. For non-
negative matrix factorization and principal component analysis, we divide each row by the
row sum.
R>H and E>K mutations are prominent features in many cancers
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NMF is an unsupervised learning method used to decompose a data matrix into a product
of two non-negative matrices representing a set of k signals and mixture coefficients. For
example if X is an m × n matrix representing the nonsynonymous mutation frequency data,
then the NMF of the data is given by
X ¼WH
where W is an m × k matrix with the k columns representing mutation signatures and H is a k
× n matrix representing the mixture coefficients that best reconstruct X. Often it is not possible
to factor X exactly, so a typical approach to solving the decomposition will optimize
min
w;H0
½DðX;WHÞ þ RðW;HÞ k ¼ 6
where D() is a loss function (often the Frobenius norm or the Kullback-Leibler divergence)
and R() is a regularization function. For our NMF analyses, we utilize the R package NMF [35]
with default choices for D() and R().
Principal component analysis (PCA)
PCA is a dimension reducing learning method designed to decompose a data matrix into a set
of orthogonal bases defined along the major axes of variation within the data. Here we com-
pute the first two principal components from our mutation frequency matrix X. The kth prin-
cipal component is represented by a vector of loadings, w(k). The first PC is then calculated as
wð1Þ ¼ argmax
wTXTXw
wTw
 
and subsequent PCs are calculated as
wðkÞ ¼ argmax
wTXTk Xkw
wTw
 
where
Xk ¼ X  
Xk  1
s
XwðsÞw
T
ðsÞ:
We use the R package prcomp to perform all PCA analyses.
Validation of NMF mutation signatures
In order to validate the mutation signatures that we discovered in our data, we sought an
orthogonal data set in which to replicate our analysis. We used the COSMIC v81 database of
somatic mutations [10]. We first filtered all mutations that were not marked as confirmed
somatic mutations. Next, as our original data set (“Alexandrov Data”) had overlapping samples
within the COSMIC database, we excluded all samples that were included in our original anal-
ysis. Finally, we excluded samples with fewer than 10 total non-synonymous mutations. This
filtering resulted in a final data set of 2,236,176 non-synonymous mutations across 15,868
samples. We named this final data set the “COSMIC Data.” We then ran NMF with k = 6 sig-
natures on the matrix of individual sample mutation frequencies as described above. Results
are shown in S4 Fig. We found that five of the six mutation signatures we originally discovered
were replicated in the COSMIC data (Fig 4).
R>H and E>K mutations are prominent features in many cancers
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Supporting information
S1 Fig. Six nonsynonymous mutation signatures identified by NMF on aggregated data.
NMF identifies six mutation signatures from data aggregated by cancer subtype including sig-
natures with (A) high R>H weights, (B) high A>T and R>H weights, (C) high E>K weights,
(D) high E>K and E>Q weights, and complex signatures (E) and (F). Amino acid mutations
to or from X represent mutations to or from stop codons. (G) The cophenetic distance and
change in residual sum of squares for different choices for the number (k) of mutation signa-
tures for the NMF analyses of data aggregated by cancer subtype. Solid lines represent NMF
on the original data and dotted lines represent NMF on this data after randomization. Six to
seven components offer a consistently good fit.
(PDF)
S2 Fig. Principal components analysis loadings on aggregated nonsynonymous mutations
for the first two principal components. (A) The first principal component separates cancers
with many R>H mutations from those with many E>K mutations, and (B) the second princi-
pal component separates these cancers from those with more complex signatures. Amino acid
mutations to or from X represent mutations to or from stop codons.
(PDF)
S3 Fig. Six nonsynonymous mutation signatures identified by NMF on individual samples.
NMF identifies six mutation signatures from individual samples (only those with >10 total
nonsynonymous mutations) including four signatures (A), (B), (C), (D) identified in the
aggregated analysis and two other complex signatures, (E) and (F). Amino acid mutations to
or from X represent mutations to or from stop codons. (G) The cophenetic distance and
change in residual sum of squares for different choices for the number (k) of mutation signa-
tures for the NMF analyses of data aggregated by individual samples. Solid lines represent
NMF on the original data and dotted lines represent NMF on this data after randomization.
Six to seven components offer a consistently good fit.
(PDF)
S4 Fig. Six nonsynonymous mutation signatures identified by NMF on individual samples
from the COSMIC database. Six mutation signatures identified by NMF from individual
samples in the COSMIC database (only those with>10 total nonsynonymous mutations) used
for validation of NMF results from Alexandrov data. Amino acid mutations to or from X rep-
resent mutations to or from stop codons. (A), (C), (E), and (F) match with previously found
signatures from the Alexandrov data.
(PDF)
S1 Table. Expected and observed mutation frequency for cancer driver genes. All Filters:
entire filtering schema (Alexandrov et al., 2013) applied; No Filtering: none of the filters
applied; Seq. Artifact Filter: only mutations defined as sequencing artifacts (Alexandrov et al.,
2013) filtered. The expected range of mutation counts for the driver genes in cancers are based
on reported mutation frequencies in the cancer genetics field and reported p53 mutation rates
(see Methods).
(PDF)
S2 Table. Total nonsynonymous mutation counts by cancer type. Data was filtered using
sequencing artifacts filter and any samples containing only synonymous mutations were elimi-
nated from analysis (see Methods). Calculated is the mean number of nonsynonymous muta-
tions per sample. Pilocytic astrocytoma samples were eliminated from analyses due to low
R>H and E>K mutations are prominent features in many cancers
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frequency of nonsynonymous mutations.
(PDF)
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